Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1182/blood-2017-08-800730 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Outcomes of Standard-Risk Multiple Myeloma Patients Who Undergo Upfront Autologous Hematopoietic Stem Cell Transplantation.
Transplant Cell Ther
December 2024
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address:
Patients with multiple myeloma (MM) without high-risk cytogenetic abnormalities are classified as having standard-risk MM (SRMM), and data focusing on their outcomes after autologous hematopoietic stem cell transplantation (autoHCT) are limited. To evaluate survival outcomes for patients with SRMM receiving autoHCT, and to elucidate factors that impact these outcomes. Single-center retrospective analysis that included consecutive MM patients who received upfront autoHCT between 2013 and 2021, had available cytogenetic information and had no high-risk chromosomal abnormalities on fluorescence in situ hybridization, defined as t(4;14), t(14;16), del(17p) or 1q21 gain or amplification.
View Article and Find Full Text PDFBackground: International Dermatology Outcome Measures (IDEOM) is a non-profit organization whose mission is to improve the availability of evidence-based, consensus-driven outcome measures for dermatological diseases. IDEOM facilitates collaboration between stakeholders from various backgrounds, including researchers, patients, physicians, and industry representatives, to develop objective benchmark metrics that enable better treatment and management of dermatologic conditions.
Summary: The 2023 IDEOM Annual Meeting was held June 23-24, 2023.
New Benchmark for Targeted Therapies in Lung Cancer: Median Progression-Free Survival for Lorlatinib in Advanced ALK+ Non-Small Cell Lung Cancer Surpasses 5 years.
J Clin Oncol
October 2024
Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN.
In the article that accompanies this editorial, Dr. Solomon and colleagues present a post-hoc analysis of investigator-assessed efficacy outcomes, safety, and biomarker analyses encompassing approximately 5 years’ worth of data from the CROWN trial (NCT03052608) of lorlatinib compared with crizotinib in patients with treatment naïve advanced / metastatic ALK+ NSCLC demonstrating a PFS benefit for lorlatinib which exceeds 5 years and a 96% probability of preventing brain metastases within this time frame. These updated data are unprecedented for the treatment of ALK+ NSCLC, and for NSCLC treated with targeted therapies in general, making a compelling argument for lorlatinib as the preferred first line ALK TKI.
View Article and Find Full Text PDFEvaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation.
Blood Adv
November 2024
Department of Pediatrics, The University of Alabama at Birmingham, Birmingham, AL.
Article Synopsis
Standardization of CD30 immunohistochemistry staining among three automated immunostaining platforms.
Pathol Int
September 2024
Department of Pathology and Laboratory Medicine, Graduate School of Medicine, Nagoya University, Nagoya, Japan.
Article Synopsis
- Identifying CD30 expression through immunohistochemistry is crucial for treating lymphomas with CD30-targeting antibody-drug conjugates, but no standardized staining protocol existed prior to this study.
- The research compared three automated immunostaining platforms (Bond III, Dako Omnis, Ventana BenchMark ULTRA) using varying dilutions of a primary antibody to determine effective staining conditions.
- The study found that adjusting antibody dilutions and cutoff values can achieve consistent CD30 staining across different platforms, with high concordance rates for diagnosing peripheral T-cell lymphomas.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!